AUTHORS
Jie Xian, PhD, Ling Zhang, BS2, George F. Widhopf II, PhD3, Can Huang, PhD4, Thomas J Kipps, MD, PhD5
AFFILIATIONS
1 University of California, San Diego Moores Cancer Center, La Jolla, California, United States
2 University of California, San Diego Moores Cancer Center, La Jolla, California, United States
3 University of California, San Diego Moores Cancer Center, La Jolla, California, United States
4 University of California, San Diego Moores Cancer Center, La Jolla, California, United States
5 University of California, San Diego Moores Cancer Center, La Jolla, California, United States
ABSTRACT
ROR1 is an oncoembryonic receptor expressed on CLL cells but largely absent from normal adult tissues and is the target of the clinical-stage antibody zilovertamab (UC961). ROR1 has established roles in Wnt5a-driven proliferation and migration, but its contribution to B-cell receptor (BCR)–proximal signaling and resistance to BCR-pathway inhibitors remains unclear. BCR signaling bifurcates into a PI3Kδ/AKT branch and a BTK-dependent calcium branch; idelalisib is used here as a pharmacologic probe of PI3Kδ-dependent survival rather than as a therapeutic endpoint.
We hypothesized that ROR1 organizes the BCR signalosome to amplify a BTK-dependent calcium axis that sustains CLL survival when PI3Kδ is inhibited, and that ROR1 blockade with zilovertamab would collapse this axis and restore drug sensitivity. Isogenic MEC1, MEC1-ROR1, and signaling-deficient MEC1-ROR1-K506A cells were used to assess idelalisib sensitivity with or without sustained BCR engagement by immobilized anti-IgM. Anti-IgM–induced calcium flux was quantified with or without idelalisib, and dependence on BTK was tested using the non-covalent BTK inhibitor pirtobrutinib. Co-immunoprecipitation and sucrose-gradient lipid-raft fractionation mapped ROR1 interactions with Lyn, CD79A, Syk, and the actin-regulatory adaptor HS1. In primary CLL cells, we examined effects of the ROR1 ligand Wnt5a on anti-IgM–induced calcium flux and on idelalisib-induced apoptosis ± zilovertamab.
Without BCR stimulation, MEC1 and MEC1-ROR1 cells showed similar idelalisib sensitivity, indicating that ROR1 does not confer generalized PI3Kδ resistance at baseline. Under sustained BCR engagement, MEC1-ROR1 cells became significantly more resistant to PI3Kδ blockade than MEC1 (rightward shift in the idelalisib dose–response curve, p<0.0001), with the greatest protection at lower drug concentrations; zilovertamab restored idelalisib sensitivity. This phenotype correlated with ROR1-specific amplification of the calcium branch: anti-IgM–induced calcium flux was markedly higher in MEC1-ROR1 than MEC1, remained preserved or further enhanced in the presence of idelalisib, and was abolished by the non-covalent BTK inhibitor pirtobrutinib, demonstrating a BTK-dependent, PI3Kδ-independent calcium axis. In primary CLL, Wnt5a pre-incubation alone did not elicit calcium flux but increased subsequent anti-IgM–induced calcium flux in a time-dependent manner (maximal at 30 minutes), consistent with ligand-driven priming of ROR1 rather than direct calcium mobilization. Sustained anti-IgM stimulation reduced idelalisib-induced apoptosis (viability 70%→86%), and addition of zilovertamab reversed this protection (52% viability), whereas isotype-control IgG had no effect (70%).
Mechanistically, ROR1 constitutively associated with Lyn, while associations with CD79A and Syk were induced only upon anti-IgM stimulation; all were lost in MEC1-ROR1-K506A cells, demonstrating dependence on ROR1 signaling. Lipid-raft fractionation showed greater recruitment of activated Syk, phospho-Lyn, and HS1 into raft fractions in ROR1-expressing cells, indicating that ROR1 pre-assembles with Lyn and, upon BCR engagement, organizes CD79A, Syk, and HS1 into the raft compartment to amplify downstream calcium signaling.
These data support a model in which ROR1 acts as a scaffold that organizes the BCR signalosome and amplifies a BTK-dependent, PI3Kδ-independent calcium axis, providing a parallel survival route when BCR input is present and PI3Kδ is pharmacologically inhibited. Idelalisib serves as a model of PI3Kδ blockade, and the ROR1-driven BTK-dependent calcium axis represents a potential “escape pathway” for CLL cells under BCR-pathway inhibition, raising the possibility that parallel calcium signaling could modulate responses to BTK inhibitors and other targeted therapies. Blockade of ROR1 with zilovertamab collapses this axis and restores drug sensitivity in vitro, providing a mechanistic rationale for exploring combinations of ROR1-targeted therapy with BTK- and PI3K-pathway inhibitors and for investigating whether ROR1-scaffolded calcium signaling is associated with resistance to BCR-pathway–inhibitor-based regimens.
DISCLOSURES
Jie Xian, PhD: No relevant conflicts of interest to declare.